Mark J Gergen
CIK 1373110 · President and CEO · last filed 2025-01-08
Mark J Gergen is a President and CEO who has filed 47 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for PSTX, was dated Jan 8, 2025. Across all open-market trades the lifetime net is −$1.4M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
4
47
-$1.36M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Poseida Therapeutics, Inc. (PSTX) Delisted | President and CEO | 0 | $9.50 | $0 | -$562.0K | 12 | 2025-01-08 |
| HALOZYME THERAPEUTICS, INC. (HTI) Delisted | SVP, Chief Operating Officer | — | — | — | $0 | 2 | 2017-02-24 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | Executive VP, COO | 5,748 | $58.70 | $337.4K | -$259.2K | 4 | 2016-01-26 |
| AMYLIN PHARMACEUTICALS INC (AMLN) Delisted | SVP, Corporate Development | 67,359 | — | — | -$536.8K | 28 | 2012-07-26 |
Recent Filings
47 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-01-08 | Poseida Therapeutics, Inc. (PSTX) Delisted | Mixed | −636,726 | $0 | EDGAR |
| 2025-01-03 | Poseida Therapeutics, Inc. (PSTX) Delisted | Tax (F) | −23,313 | -$223.8K | EDGAR |
| 2024-12-11 | Poseida Therapeutics, Inc. (PSTX) Delisted | Mixed | — | -$200.4K | EDGAR |
| 2024-11-27 | Poseida Therapeutics, Inc. (PSTX) Delisted | Mixed | — | -$194.7K | EDGAR |
| 2024-03-04 | Poseida Therapeutics, Inc. (PSTX) Delisted | Tax (F) | −34,157 | -$141.1K | EDGAR |
| 2024-02-02 | Poseida Therapeutics, Inc. (PSTX) Delisted | Tax (F) | −47,162 | -$160.8K | EDGAR |
| 2024-01-04 | Poseida Therapeutics, Inc. (PSTX) Delisted | Grant (A) | +125,000 | $0 | EDGAR |
| 2023-03-02 | Poseida Therapeutics, Inc. (PSTX) Delisted | Grant (A) | +269,586 | $0 | EDGAR |
| 2023-02-03 | Poseida Therapeutics, Inc. (PSTX) Delisted | Tax (F) | −31,819 | -$222.7K | EDGAR |
| 2022-02-01 | Poseida Therapeutics, Inc. (PSTX) Delisted | Grant (A) | +357,200 | $0 | EDGAR |